Skip to Main Content

Novavax, Inc. Securities Fraud Class Action

View Complaint
COMPANY         Novavax, Inc
COURT United States District Court for the District of Maryland
CASE NUMBER 21-cv-02910
JUDGE The Honorable Theodore D. Chuang
CLASS PERIOD March 2, 2021 and October 19, 2021
SECURITY TYPE  All Securities

Case Background:

A class action lawsuit has been filed on behalf of those who purchased or acquired Novavax, Inc. (“Novavax”) (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, both dates inclusive (the “Class Period”).

The complaint alleges that throughout the Class Period, the Defendants made false and/or misleading statements and/or failed to disclose that: (1) Novavax overstated its manufacturing capabilities and downplayed manufacturing issues that would impact its approval timeline for NVX-CoV2373; (2) as a result, Novavax was unlikely to meet its anticipated EUA regulatory timelines for NVX-CoV2373; (3) accordingly, Novavax overstated the regulatory and commercial prospects for NVX-CoV2373; and (4) as a result, Novavax’s public statements were materially false and misleading at all relevant times.

Current Status of Case:

On December 1, 2023, the parties advised the Court that they had agreed to settle the action. On January 23, 2024, the Court issued an Order granting Lead Plaintiffs’ Motion for Preliminary Approval of Class Action Settlement. On May 24, 2024, The Court entered Orders Approving Plan of Allocation, Awarding Attorney Fees, Final Approval of Settlement and entered Final Order and Judgment. This action has concluded. 

The deadline to file a claim is May 18, 2024.  If you have any questions or need further information about this settlement, you may go to the following website www.strategicclaims.net/novavax/, or you can contact the claims administrator, Strategic Claims Services at 1-866-274-4004. 

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP:  Jon Naji, Esq. (484) 270-1453; or via e-mail at info@ktmc.com.  If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Please complete this form relating to your transactions for Novavax, Inc. (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, both dates inclusive (the “Class Period”).

You may also contact Jon Naji, Esq. (484) 270-1453; or toll free at (844) 887-9500; or you may submit your information via email at info@ktmc.com; or you may click here to print a PDF of this form.

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Novavax, Inc. prior to the Class Period?
Are you a current or former employee of Novavax, Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email